Text

Efficacy of Chloroquine, Chloroquine Plus Sulphadoxine-Pyrimethamine, and Amodiaquine for treatment of Vivax Malaria in Bangka Island, Indonesia: a Randomized Trial

---

Plasmodium vivax malaria resistant to chloroquinenis alarming in Indonesia and has been also reported in other countries. An alternative drug is needed. The study was a prospective evaluation and a comparative study of the therapeutic efficacy of choloquine 25 mg base/kg bw for 3 days (CQ3 plus sulfadoxine-pyrimethamine based on pyrimethamine of 1.23 mg/kg bw single dose (SPI) [CQ3=SPI, n=84] and amodiaquine 25 mg base/kg bw for 3 days (AQ3, n=83) in symptomatic vivax malaria patients in children and adults. The new version of 2001 WHO test system was used in this study. PCR for genotyping was also done to validate and confirmthe treatment outcomes. The therapeutic efficacy of CQ3+CQ3+SPI and AQ3 on day 14 were very high 4%, 97.4% and 98.8% and dropped on day 28 (81.7% and 96.2% by evaluable analysis: 78.9%. 82.0% and 92.5% after confirmation with PCR: and 74.7%, 78.0% and 90.2% by intention to treat analysis). Most of the ACPR cases (>96% showed hematological recovery. Gametocyte carriages were documented on day 7(2,9%, 1.3% and 1.2%), day 14 (4.3% and 1.2%) and day 28 (6.6%, 4.2% and none) in CQ3, CQ3+SPI and AQ3 group. Of these 3 regimens, AQ3 showed a better therapeutic afficacy than CQ3 and combined CQ3+SPI by day 28. Introducing primaquine at the beginning of treatment day or giving a radical treatment in vivax malaria may improve the cure rate.

---

Ketersediaan

Informasi Detail

Judul Seri

-

No. Panggil

Medical Joural of Indonesia, 17(2):96-106

Penerbit

Jakarta : Fk. Universitas Indonesia., 2008

Deskripsi Fisik

7p.

Bahasa

English

ISBN/ISSN

0853-1773

Klasifikasi

-

Tipe Isi

-

Tipe Media

-

Tipe Pembawa

-

Edisi

-

Subjek

malaria
chloroquine
SULFADOXINE

Info Detail Spesifik

-

Pernyataan Tanggungjawab

-

Versi lain/terkait

Lampiran Berkas

Komentar

---

Anda harus masuk sebelum memberikan komentar